Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings.
asthma
comorbidity
multidimensional assessment
quality of life
targeted therapy
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
18
09
2019
revised:
06
02
2020
accepted:
20
02
2020
pubmed:
28
2
2020
medline:
1
6
2021
entrez:
28
2
2020
Statut:
ppublish
Résumé
Severe asthma imposes a significant burden on individuals, families and the healthcare system. Treatment is complex, due to disease heterogeneity, comorbidities and complexity in care pathways. New approaches and treatments improve health outcomes for people with severe asthma. However, emerging multidimensional and targeted treatment strategies require a reorganisation of asthma care. Consensus is required on how reorganisation should occur and what areas require further research. The Centre of Excellence in Severe Asthma convened three forums between 2015 and 2018, hosting experts from Australia, New Zealand and the UK. The forums were complemented by a survey of clinicians involved in the management of people with severe asthma. We sought to: (i) identify areas of consensus among experts; (ii) define activities and resources required for the implementation of findings into practice; and (iii) identify specific priority areas for future research. Discussions identified areas of unmet need including assessment and diagnosis of severe asthma, models of care and treatment pathways, add-on treatment approaches and patient perspectives. We recommend development of education and training activities, clinical resources and standards of care documents, increased stakeholder engagement and public awareness campaigns and improved access to infrastructure and funding. Further, we propose specific future research to inform clinical decision-making and develop novel therapies. A concerted effort is required from all stakeholders (including patients, healthcare professionals and organisations and government) to integrate new evidence-based practices into clinical care and to advance research to resolve questions relevant to improving outcomes for people with severe asthma.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-180Subventions
Organisme : AstraZeneca
Organisme : National Health and Medical Research Council (Centre of Research Excellence in Severe Asthma)
ID : APP1078579
Informations de copyright
© 2020 Royal Australasian College of Physicians.
Références
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-73.
von Bulow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract 2014; 2: 759-67.
Nordon C, Grimaldi-Bensouda L, Pribil C, Nachbaur G, Amzal B, Thabut G et al. Clinical and economic burden of severe asthma: a French cohort study. Respir Med 2018; 144: 42-9.
Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol 2015; 136: 1488-95.
Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J 2018; 52: 1800703.
Voorham J, Xu X, Price DB, Golam S, Davis J, JLJ Z et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy 2019; 74: 273-83.
Foster JM, McDonald VM, Guo M, Reddel HK. "I have lost in every facet of my life": the hidden burden of severe asthma. Eur Respir J 2017; 50: 1700765.
Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC, Sullivan S et al. Direct healthcare costs associated with asthma in British Columbia. Can Respir J 2010; 17: 74-80.
Hiles SA, Harvey ES, McDonald VM, Peters M, Bardin P, Reynolds PN et al. Working while unwell: workplace impairment in people with severe asthma. Clin Exp Allergy 2018; 48: 650-62.
Clark VL, Gibson PG, Genn G, Hiles SA, Pavord ID, McDonald VM. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology 2017; 22: 1262-75.
McDonald VM, Maltby S, Gibson PG. Severe asthma: can we fix it? Prologue to seeking innovative solutions for severe asthma. Respirology 2017; 22: 19-20.
Severe Asthma in Australia. Med J Aust 2018.
McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report. Eur Respir J 2019; 53: 1802058.
McDonald VM, Hiles SA, Godbout K, Harvey ES, Marks GB, Hew M et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology 2019; 24: 37-47.
Denton E, Hore-Lacy F, Radhakrishna N, Gilbert A, Tay T, Lee J et al. Severe asthma global evaluation (SAGE): an electronic platform for severe asthma. J Allergy Clin Immunol Pract 2019; 7: 1440-9.
Harvey E, Langton D, Powell H, Gibson PG. Clinical response to mepolizumab in patients with severe eosinophilic asthma. Respirology 2019; 24: 42.
McDonald VM, Clark VL, Cordova-Rivera L, Wark PAB, Baines KJ, Gibson PG. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J 2020; 55: 1901509.
Gibeon D, Heaney LG, Brightling CE, Niven R, Mansur AH, Chaudhuri R et al. Dedicated severe asthma services improve health-care use and quality of life. Chest 2015; 148: 870-6.
Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirology 2017; 22: 651-61.
Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G et al. After asthma: redefining airways diseases. Lancet 2018; 391: 350-400.
Traister RS, Fajt ML, Petrov AA. The morbidity and cost of vocal cord dysfunction misdiagnosed as asthma. Allergy Asthma Proc 2016; 37: 25-31.
Radhakrishna N, Tay TR, Hore-Lacy F, Hoy R, Dabscheck E, Hew M. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med 2016; 117: 166-73.
Denton E, Bondarenko J, O'Hehir RE, Hew M. Breathing pattern disorder in difficult asthma: characteristics and improvement in asthma control and quality of life after breathing re-training. Allergy 2019; 74: 201-3.
Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-24.
Chung LP, Hew M, Bardin P, McDonald VM, Upham JW. Managing patients with severe asthma in Australia: current challenges with the existing models of care. Intern Med J 2018; 48: 1536-41.
Chung LP, Johnson P, Summers Q. Models of care for severe asthma: the role of primary care. Med J Aust 2018; 209: S34-40.
Hains I, Meyers J, Sterling K, Yoo J, Reddel H, Weston C. Difficult-to-treat and severe asthma in general practice: delivery and evaluation of an educational program. BMC Fam Pract 2019; 20: 99.
McDonald VM, Vertigan AE, Gibson PG. How to set up a severe asthma service. Respirology 2011; 16: 900-11.
Tay TR, Lee J, Radhakrishna N, Hore-Lacy F, Stirling R, Hoy R et al. A structured approach to specialist-referred difficult asthma patients improves control of comorbidities and enhances asthma outcomes. J Allergy Clin Immunol Pract 2017; 5: 956-64 e3.
Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 2010; 376: 803-13.
McDonald VM, Maltby S, Reddel HK, King GG, Wark PA, Smith L et al. Severe asthma: current management, targeted therapies and future directions - a roundtable report. Respirology 2017; 22: 53-60.
Ramsahai JM, Wark PA. Appropriate use of oral corticosteroids for severe asthma. Med J Aust 2018; 209: S18-21.
Menzies-Gow A, Canonica GW, Winders TA, Correia de Sousa J, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Adv Ther 2018; 35: 1485-96.
Correll PK, Poulos LM, Ampon R, Reddel HK, Marks GB. Respiratory Medication Use in Australia 2003-2013: Treatment of Asthma and COPD [Cat. No. ACM 31. Edn]. Australian Institute of Health and Welfare: Canberra; 2015.
AIHW. Asthma Snapshot. AIHW: Canberra; 2017.
Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11: 54-61.
McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics 2018; 36: 957-71.
Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res 2018; 4: 00125-2017.
GINA. Difficult-to-treat & severe asthma in adolescent and adult patients: diagnosis and management. Pocket Guide v2.0; 2019.
McDonald VM, Kennington E, Hyland ME. Understanding the experience of people living with severe asthma. In: Chung KF, Israel E and Gibson PG, eds ERS Monograph: Severe Asthma. Lausanne, Switzerland: European Respiratory Society; 2019; 16-29.
Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010; 181: 566-77.
Clark VL, Gibson PG, McDonald VM. What severe asthma treatment outcomes matter to patients? Respirology 2019; 24: 44.
Cordova-Rivera L, Gibson PG, Gardiner PA, Powell H, McDonald VM. Physical activity and exercise capacity in severe asthma: key clinical associations. J Allergy Clin Immunol Pract 2018; 6: 814-22.
Laba TL, Jan S, Zwar NA, Roughead E, Marks GB, Flynn AW et al. Cost-related underuse of medicines for asthma-opportunities for improving adherence. J Allergy Clin Immunol Pract 2019; 7: 2298-2306.